Clinical atovaquone-proguanil resistance of Plasmodium falciparum associated with cytochrome b codon 268 mutations

Microbes and Infection

Volumn 8, Issue 11, 2006, Pages 2599-2604

  Musset, Lise ^a,b   Bouchaud, Olivier ^c   Matheron, Sophie ^b   Massias, Laurent ^b   Le Bras, Jacques ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b BICHAT HOSPITAL   (France)

^c AVICENNE HOSPITAL   (France)

Author keywords

Atovaquone; Chemotherapy; Cytochrome b; Malarone; Plasmodium falciparum; Proguanil; Resistance

Indexed keywords

ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; CYCLOGUANIL; CYTOCHROME B; PROGUANIL;

ADOLESCENT; ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CODON; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG SENSITIVITY; FEMALE; GENE MUTATION; HUMAN; IN VITRO STUDY; INFECTION RESISTANCE; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; MALARIA; MALE; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT FAILURE;

ADOLESCENT; ADULT; AMINO ACID SUBSTITUTION; ANIMALS; ANTIMALARIALS; ATOVAQUONE; CHLOROGUANIDE; CODON; CYTOCHROMES B; DRUG RESISTANCE; FEMALE; GENOTYPE; HUMANS; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; MUTATION; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM; PROGUANIL;

PLASMODIUM FALCIPARUM;

EID: 33750024079     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2006.07.011     Document Type: Article

References (16)

1. Fry M., and Pudney M. Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4′-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquino ne (566C80). Biochem. Pharmacol. 43 (1992) 1545-1553
2. Srivastava I.K., and Vaidya A.B. A mechanism for the synergistic antimalarial action of atovaquone and proguanil. Antimicrob. Agents Chemother. 43 (1999) 1334-1339
3. Fivelman Q.L., Butcher G.A., Adagu I.S., Warhurst D.C., and Pasvol G. Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria. [Online]. Available from: Malar. J. 1 (2002). http://www.malariajournal.com/content/1/1/1 (accessed 11.01.05)
4. Schwartz E., Bujanover S., and Kain K.C. Genetic confirmation of atovaquone-proguanil-resistant Plasmodium falciparum malaria acquired by a nonimmune traveler to East Africa. Clin. Infect. Dis. 37 (2003) 450-451
5. Färnert A., Lindberg J., Gil P., Swedberg G., Berqvit Y., Thapar M.M., Lindegardh N., Berezcky S., and Björkman A. Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reports. BMJ 326 (2003) 628-629
6. Wichmann O., Muehlberger N., Jelinek T., Alifrangis M., Peyerl-Hoffmann G., Mühlen M., Grobusch M.P., Gascon J., Matteelli A., Laferl H., Bisoffi Z., Ehrhardt S., Cuadros J., Hatz C., Gjørup I., McWhinney P., Beran J., da Cunha S., Schulze M., Kollaritsch H., Kern P., Fry G., Richter J., and The European Network on Surveillance of Imported Infectious Diseases. Screening for mutations related to atovaquone/proguanil resistance in treatment failures and other imported isolates of Plasmodium falciparum in Europe. J. Infect. Dis. 190 (2004) 1541-1546
7. Kuhn S., Gill M.J., and Kain K.C. Emergence of atovaquone-proguanil resistance during treatment of Plasmodium falciparum malaria acquired by a non-immune north American traveller to west Africa. Am. J. Trop. Med. Hyg. 72 (2005) 407-409
8. Meshnick S.R., and Trumpower B. Multiple cytochrome b mutations may cause atovaquone resistance. (letter). J. Infect. Dis. 191 (2005) 822
9. World Health Organization. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. [Online]. Available from: (2003). http://www.who.int/malaria/includes_en/whomalariapublications19982004.ht m (accessed 09.05.05)
10. Management and prevention of imported Plasmodium falciparum malaria. The 12th Consensus Conference of Anti-infectious. Therapy of the French-speaking Society of Infectious Diseases, 14 April 1999. Arch. Pediatr. 7 (2000) 201-208
11. Musset L., Pradines B., Parzy D., Durand R., Bigot P., and Le Bras J. Apparent absence of atovaquone/proguanil resistance in 477 Plasmodium falciparum isolates from untreated French travellers. J. Antimicrob. Chemother. 57 (2006) 110-115
12. Jafari S., Le Bras J., Bouchaud O., and Durand R. Plasmodium falciparum clonal population dynamics during malaria treatment. J. Infect. Dis. 189 (2004) 195-203
13. Hussein Z., Eaves J., Hutchinson D.B., and Canfield C.J. Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. Clin. Pharmacol. Ther. 61 (1997) 518-530
14. 1 complex and confer anti-malarial drug resistance in Saccharomyces cerevisiae. J. Biol. Chem. 280 (2005) 17142-17148
15. 0 site inhibitor bound. J. Biol. Chem. 278 (2003) 31303-31311
16. Fidock D.A., and Wellems T.E. Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 10931-10936